Channel Medsystems Secures $30 Million in Series C Funding
Channel Medsystems, a medical technology company based in Berkeley, California, has announced a successful Series C funding round, securing $30 million. The round was led by InnovaHealth Partners. Channel Medsystems focuses on providing solutions for women suffering from heavy menstrual bleeding through its Cerene Endometrial Cryotherapy, a quick and minimally invasive treatment option.
Leadership and Vision
Nelson Whistance, President and CEO of Channel Medsystems, emphasized the significance of this funding round in strengthening the company’s commercial strategy. "This Series C investment represents increasing investor confidence in our updated commercial strategy and the significant market opportunity that exists for our Cerene platform," Whistance stated.
Strategic Use of Funds
The newly acquired funds will be utilized to enhance the commercial expansion of the Cerene Cryotherapy platform. Specific initiatives include expanding the commercial organization, increasing awareness among physicians and patients, and strengthening professional education and training programs. The investment will also support efforts to generate clinical evidence, develop the market further, and improve infrastructure to sustain long-term growth.
Looking Ahead
Channel Medsystems aims to use this investment to broaden access to Cerene for women experiencing heavy menstrual bleeding, improving the standard of care and offering a less invasive treatment option.